ArticleHematological oncology2026

Cost-Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective.

Yongtao He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.